fakhravac fakhravac fakhravac (persian: واکسن فخرا) is a covid-19 vaccine developed in iran by the organization of defensive innovation and research, a subsidiary of iran's ministry of defense. it's the third iranian covid-19 vaccine reaching clinical trials. it's currently in phase iii. it has received emergency use authorization in iran on 9 september 2021. fakhravaca vial of fakhravacvaccine descriptiontargetsars-cov-2vaccine typeinactivatedclinical dataother namesfakhra, mivacroutes ofadministrationintramuscularlegal statuslegal status emergency use authorization: irn part of a series on thecovid-19 pandemicscientifically accurate atomic model of the external structure of sars-cov-2. each "ball" is an atom. covid-19 (disease) sars-cov-2 (virus) cases deaths timeline 2019 2020 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2021 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november responses december responses 2022 january responses february responses march responses april responses may responses june responses july responses august responses september responses october responses november december 2023 january february march april may locations by country and territory africa antarctica asia europe north america oceania south america by conveyance cruise ships naval ships international response endemic phase evacuations face masks international aid investigations into origin lockdowns by country misinformation by governments fake treatments social distancing software travel united nations world health organization wto ip waiver undercounting of deaths covid-19 apps zero-covid national responses africa china european union germany ghana india ireland netherlands new zealand nigeria philippines russia sweden uk government us federal government vietnam medical response disease testing breathalyzer development drug development drug repurposing public health mitigation vaccines history research vitt deployment authorizations operation warp speed misinformation and hesitancy us vaccine card vaccine passports current vaccines coronavac covaxin convidecia janssen medigen moderna novavax oxford–astrazeneca pfizer–biontech sinopharm bibp sputnik v variants variants of concern alpha beta gamma delta omicron other variants epsilon zeta eta theta iota kappa lambda mu cluster 5 lineage b.1.617 economic impact and recession arts and culture aviation cannabis cinema films disney fashion financial markets food industry food security journalism music performing arts retail shipping television us sportscasting programs tourism video games by country canada india ireland malaysia new zealand russia uk us by sport association football baseball basketball combat sports cricket disc golf gaelic games gridiron football ice hockey motorsport rugby league impacts animals black people crime death rates by country disability domestic violence emergency evacuations education female environment hospitals language lgbt community long-term care media coverage mental health symptoms migration military notable deaths other health issues politics diplomacy popular culture protests pregnancy prisons religion catholic church hajj science and technology social media strikes suicides telehealth xenophobia and racism society ireland malaysia new zealand russia uk us covid-19 portal the vaccine is named after the iranian nuclear scientist mohsen fakhrizadeh. according to the iranian authorities, he was working on a vaccine in response to the covid-19 pandemic in iran. fakhrizadeh was assassinated in november 2020 in an attack iran and us intelligence attributed to israel. medical uses it requiring two doses given by intramuscular injection 3 weeks apart. pharmacology fakhravac is an inactivated virus-based vaccine. manufacturing in august 2021, production capacity of the vaccine is reported to be 1 million dose per month and is planned to be "multiplied in a few months ". in october 2021, the production has reported to be stopped amid iran's growing vaccine imports. in january 2022, the director general of health of the ministry of defense announced that the first shipment (around 462,000 doses) of the vaccine had been delivered to the iranian ministry of health. clinical trials clinical trials of fakhravac phase registration number start number of participants age of participants total vaccine control i irct20210206050259n1 8 march 2021 135 96? 39? (placebo) 18–55 years ii irct20210206050259n2 8 june 2021 500 250 250 (placebo) 18–70 years iii irct20210206050259n3 29 august 2021 41,128 20,564 20,564 (sinopharm bibp vaccine) >18 years authorizations full authorization emergency authorization